Product Description
Cefepime injection is used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. (Sourced from: https://www.mayoclinic.org/drugs-supplements/cefepime-injection-route/side-effects/drg-20073408?p=1)
Mechanisms of Action: LACTB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Pneumonia, Bacterial | Urinary Tract Infections | Nephritis | Pyelonephritis | Pneumonia
Known Adverse Events: Headache | Diarrhea
Company: Allecra
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, China, Croatia, Czech Republic, Estonia, France, Greece, Hungary, India, Japan, Latvia, Lithuania, Mexico, Peru, Poland, Slovakia, Spain, United States
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Communicable Diseases|Intraabdominal Infections|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Pyelonephritis|Urinary Tract Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CERTAIN-2 | P3 |
Not yet recruiting |
Pneumonia, Ventilator-Associated|Pneumonia, Bacterial |
2027-06-01 |
|
| 2022-001832-27 | P2 |
Active, not recruiting |
Pyelonephritis|Urinary Tract Infections |
2026-02-16 |
|
| AT-202 | P2 |
Unknown Status |
Pyelonephritis|Urinary Tract Infections |
2025-12-31 |
|
| AT-202 | P2 |
Recruiting |
Urinary Tract Infections |
2025-09-30 |
24% |